Top 5 Performing Stocks To Own For 2018

Bank of America’s (NYSE:BAC) shares suddenly dropped last week, slumping ~6 percent on Tuesday as investors rushed to sell financials and take profits in stocks that have soared since the U.S. election. Republicans also don’t appear to be able to score legislative victories as easily as investors thought, which raises concerns over the sustainability of the Trump rally.

Let’s first agree that Bank of America has been a very good investment already in the last several months, but especially over the last year. Believe it or not, but an investment in Bank of America has returned ~70 percent since March 28, 2016, outperforming other financial stocks as well as major stock market indices by a wide margin.

Top 5 Performing Stocks To Own For 2018: Dave & Buster's Entertainment, Inc.(PLAY)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap restaurant and entertainment stockDave & Busters Entertainment Inc (NASDAQ: PLAY)updated guidance for its fiscal 2017 (which ends on February 4, 2018):

  • [By Stephan Byrd]

    Equities analysts expect Dave & Buster’s (NASDAQ:PLAY) to report $324.81 million in sales for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for Dave & Buster’s’ earnings, with estimates ranging from $320.19 million to $332.00 million. Dave & Buster’s posted sales of $304.15 million during the same quarter last year, which suggests a positive year over year growth rate of 6.8%. The firm is scheduled to report its next quarterly earnings report on Tuesday, June 5th.

  • [By Trey Thoelcke]

    Dave & Buster’s Entertainment Inc.’s (NASDAQ: PLAY) fiscal fourth-quarter report is scheduled for Tuesday after the markets close. The consensus estimates are $0.60 in earnings per share (EPS) on $305.49 million in revenue. The shares ended the week at $41.74. The consensus price target is $65.33, and the 52-week trading range is $41.04 to $73.48.

  • [By Matt Hogan]

    Casual-dining chains have not been winners during this economic expansion. Millenials, with their need for more social media-worthy experiences, have been blamed for the decline in conjunction with Baby Boomers moving onto fixed incomes as they retire.

    Dave & Buster's Entertainment Inc (NASDAQ: PLAY) provides an eat, drink, play, and watch experience for consumers. This hybrid entertainment/dining experience has fared well since going public in 2012, attracting higher-income adults in the 21-39 age range.
    Poor same-store sales last quarter knocked the premium off the stock price, but top and bottom-line growth were still strong. Margins and efficiency ratios top its competitors, and Wall Street and quant valuation models agree that there is a strong upside for this diamond in the casual-dining rough.

    You'll Probably Want to Sit Down for This

    Casual dining, the traditional sit-down, full-service restaurant experience is getting hit by demographics. Millennials want hip, social-media worthy experiences and retiring Baby Boomers are thrifty on their fixed incomes. Headlines such as "Millennials Are Killing Chains Like Buffalo Wild Wings And Applebee's" are not uncommon.

Top 5 Performing Stocks To Own For 2018: Sage Therapeutics, Inc.(SAGE)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Friday was a poor day on Wall Street, as the Dow Jones Industrials fell 200 points and other major benchmarks lost about 1%. Rising bond yields were a major source of consternation among those following the financial markets, with the 10-year Treasury hitting 2.95% and helping to send mortgage rates sharply higher. Even though earnings season has gone fairly well for many companies, some investors are also starting to realize that political issues are likely to cloud the outlook for the U.S. economy in the coming months, creating more uncertainty that could stymie further market gains. Some bad news affecting individual companies also added to the negative mood. Stanley Black & Decker (NYSE:SWK), ManpowerGroup (NYSE:MAN), and Sage Therapeutics (NASDAQ:SAGE) were among the worst performers on the day. Here’s why they did so poorly.

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By ]

    Cramer was bearish on Geron (GERN) , Mitek Systems (MITK) , AK Steel Holding (AKS) , Sage Therapeutics (SAGE) and AbbVie (ABBV) .

    Search Jim Cramer’s “Mad Money” trading recommendations using our exclusive “Mad Money” Stock Screener.

Top 5 Performing Stocks To Own For 2018: ZIOPHARM Oncology Inc(ZIOP)

Advisors’ Opinion:

  • [By Paul Ausick]

    Ziopharm Oncology Inc. (NASDAQ: ZIOP) dropped more than 10% Tuesday to post a 52-week low of $3.77 after closing at $4.20 on Monday. The 52-week high is $7.88. Volume was around 3.7 million, more than double the daily average. The company reported Tuesday on progress of two platforms it is developing and investors did not like what they heard.

  • [By Todd Campbell]

    It garnered a lot of attention in 2015 when Ziopharm (NASDAQ:ZIOP) announced it would use its “sleeping beauty” technology to improve upon chimeric antigen receptor T-cell therapies that it was developing. Then, its mosquitoes that are engineered so that they can’t reproduce and spread disease won investor interest during the Zika virus outbreak in 2015 and 2016.

  • [By Keith Speights]

    Over the last 12 months, bluebird bio (NASDAQ:BLUE) stock has more than doubled. During the same period, Ziopharm Oncology’s (NASDAQ:ZIOP) share price has tumbled over 30%. That’s the past, though. Which of these two clinical-stage biotech stocks is the better pick for investors now?

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Ziopharm Oncology (ZIOP)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Stellar Biotechnologies, Inc. (NASDAQ: SBOT) fell 42 percent to $2.25 in pre-market trading after dropping 31.45 percent on Thursday. Stellar Biotechnologies priced 2.075 million units at price of $2.65 per unit.
    Symantec Corporation (NASDAQ: SYMC) shares fell 25.2 percent to $21.82 in pre-market trading. Symantec reported better-than-expected earnings for its fourth quarter, but issued weak second-quarter guidance.
    AGM Group Holdings Inc. (NASDAQ: AGMH) shares fell 9.5 percent to $10 in pre-market trading after surging 7.79 percent on Thursday.
    ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) fell 8.9 percent to $4.11 in pre-market trading after the company posted wider-than-expected Q1 loss.
    Redfin Corporation (NASDAQ: RDFN) fell 8.6 percent to $21.00 in pre-market trading after reporting Q1 results.
    Geron Corporation (NASDAQ: GERN) fell 8.3 percent to $3.33 in pre-market trading. Geron posted a Q1 loss of $0.04 per share.
    Talend S.A. (NASDAQ: TLND) shares fell 6 percent to $56 in pre-market trading after reporting Q1 results.
    Flotek Industries, Inc. (NYSE: FTK) fell 5.4 percent to $3.54 in pre-market trading after dropping 2.35 percent on Thursday.
    Halozyme Therapeutics, Inc. (NASDAQ: HALO) fell 5.1 percent to $18.95 in pre-market trading after reporting Q1 results.
    Yelp Inc. (NYSE: YELP) shares fell 4.9 percent to $45.40 in pre-market trading. Yelp reported stronger-than-expected results for its first quarter on Thursday.
    Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shares fell 3.3 percent to $7.50 in pre-market trading after dropping 4.32 percent on Thursday

Top 5 Performing Stocks To Own For 2018: NF Energy Saving Corporation(NFEC)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Blink Charging Co. (NASDAQ: BLNK) shares jumped 26.5 percent to $6.9042. Blink Charging reported Q1 net income of $2.2 million, versus a year-ago net loss of $3.1 million.
    Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) shares climbed 17.4 percent to $3.11. Eleven Biotherapeutics posted a Q1 loss of $0.11 per share.
    Flanigan's Enterprises, Inc. (NYSE: BDL) shares jumped 17 percent to $27.97 following Q2 results. Flanigan's Enterprises posted Q2 earnings of $0.75 per share on sales of $29.456 million.
    Borqs Technologies, Inc. (NASDAQ: BRQS) rose 15.8 percent to $8.05 after reporting Q1 results.
    Abaxis, Inc. (NASDAQ: ABAX) jumped 15.3 percent to $82.75. Zoetis Inc. (NYSE: ZTS) announced plans to acquire Abaxis for $83 per share in cash.
    21Vianet Group, Inc. (NASDAQ: VNET) gained 15.1 percent to $6.33.
    Gemphire Therapeutics Inc. (NASDAQ: GEMP) rose 13.8 percent to $6.27.
    Enphase Energy, Inc. (NASDAQ: ENPH) gained 12.8 percent to $5.98. H.C. Wainwright initiated coverage on Enphase Energy with a Buy rating.
    PetIQ Inc (NASDAQ: PETQ) shares surged 12.1 percent to $21.68 after reporting a first-quarter sales beat.
    NF Energy Saving Corporation (NASDAQ: NFEC) climbed 11.6 percent to $2.399.
    Allied Healthcare Products, Inc. (NASDAQ: AHPI) surged 11.4 percent to $3.0643.
    Boot Barn Holdings, Inc. (NYSE: BOOT) gained 11.1 percent to $24.40 after the company reported upbeat results for its fourth quarter and issued strong first-quarter earnings guidance.
    Ascena Retail Group, Inc. (NASDAQ: ASNA) rose 10.9 percent to $3.16.
    Sea Limited (NYSE: SE) gained 10.1 percent to $11.71 after reporting Q1 results.
    GEE Group, Inc. (NYSE: JOB) climbed 7.9 percent to $2.61 following Q2 results.
    The ONE Group Hospitality, Inc. (NASDAQ: STKS) gained 7.6 percent to $2.41 after reporting Q1 results.
    Biolinerx Ltd/S ADR (NASDAQ: BLRX) rose 7.3 percent to $0.8798 after the company was granted a patent approval. The clinical-st

Top 5 Performing Stocks To Own For 2018: China Petroleum & Chemical Corporation(SNP)

Advisors’ Opinion:

  • [By Max Byerly]

    News headlines about Sinopec (NYSE:SNP) have been trending somewhat positive on Saturday, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sinopec earned a coverage optimism score of 0.23 on Accern’s scale. Accern also gave headlines about the oil and gas company an impact score of 45.9265677546286 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

  • [By Joseph Griffin]

    Sinopec (NYSE:SNP) announced a Semi-Annual dividend on Wednesday, March 28th, Zacks reports. Investors of record on Friday, May 25th will be paid a dividend of 4.568 per share by the oil and gas company on Thursday, June 21st. The ex-dividend date is Thursday, May 24th.

Leave a Reply

Your email address will not be published. Required fields are marked *